From the Department of Cell Biology and Molecular Medicine, Rutgers-New Jersey Medical School, Newark.
Circ Res. 2016 Sep 2;119(6):714-7. doi: 10.1161/CIRCRESAHA.116.309512.
There are multiple reasons for the failure to successfully translate new drugs to the clinics. One reason, noted by others, is the lack of reproducibility of studies and the problems with accuracy and rigor. However, another reason for translational failure has not been emphasized by others, i.e., the lack of state-of-the-art cardiovascular measurements, due to effects of anesthesia, lack of direct measurements of cardiovascular function, and problems of species differences. In part, this is due to the impact of molecular medicine on traditional physiology, which not only affects priority for publication in top tier journals, but also funding priorities for NIH study sections, resulting in the closure of almost all cardiovascular physiology laboratories, leaving the cardiovascular physiology in many molecular publications to incidental data that are not peer reviewed and in many cases are inaccurate. It is the plea of this Viewpoint to correct this deficiency in expertise in our scientific community, a project with no simple solutions.
新药未能成功转化为临床应用有多种原因。其他人指出的一个原因是研究的可重复性差，以及准确性和严谨性方面存在问题。然而，另一个导致转化失败的原因尚未得到其他人的重视，即由于麻醉的影响、缺乏对心血管功能的直接测量以及物种差异等问题，缺乏最先进的心血管测量技术。在某种程度上，这是由于分子医学对传统生理学的影响所致，这不仅影响了顶级期刊的优先发表，也影响了 NIH 研究小组的资金优先事项，导致几乎所有心血管生理学实验室关闭，使得许多分子出版物中的心血管生理学内容仅依赖于未经同行评审且在许多情况下不准确的偶然数据。本文观点恳请科学界纠正这一专业知识的不足，但这是一个没有简单解决方案的项目。
